Laura Sterian Ward - Genetic Mutations

Author Information

Laura Sterian Ward is a notable researcher affiliated with the Laboratory of Cancer Molecular Genetics at the Faculty of Medical Sciences, University of Campinas (Unicamp) in Campinas, São Paulo, Brazil. Her work is primarily centered on the molecular genetics of cancer, with a strong focus on thyroid cancer research. Her affiliation with a leading research institution underscores her active involvement in advancing the understanding of cancer biology and its implications for clinical practice.

Research Contributions

Laura Sterian Ward has made significant contributions to the field of thyroid cancer research, particularly concerning the immune microenvironment and molecular markers in thyroid nodules. Her research has explored the clinical utility of various genetic and molecular markers, such as TGFB1 and its receptors, as well as the co-expression of p53 and MDM2 in thyroid follicular lesions. Additionally, her work has addressed broader topics such as the impact of Body Mass Index on COVID-19 prognosis and the role of cell adhesion molecules in thyroid tumors. Her studies often employ advanced techniques such as immunohistochemistry and in silico analysis to provide insights into cancer biology and potential therapeutic targets.

Aliases

Throughout her career, Laura Sterian Ward has published under several aliases including L S Ward, Laura S. Ward, Laura Ward, and L. S. Ward. These variations reflect different naming conventions used across publications and databases but all refer to the same author.

Publication and Citation Metrics

Metric	Value
Total Citation Count	3802
h-index	35
Total Paper Count	180

Publications:

Translating the immune microenvironment of thyroid cancer into clinical practice.

DOI: 10.1530/ERC-21-0414

Year: 2022

Clinical utility of TGFB1 and its receptors (TGFBR1 and TGFBR2) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis.

DOI: 10.20945/2359-3997000000330

Year: 2021

Clinical utility of the imunohistochemical co-expression of p53 and MDM2 in thyroid follicular lesions.

DOI: 10.1016/j.anndiagpath.2021.151766

Year: 2021

The immune landscape of the microenvironment of thyroid cancer is closely related to differentiation status

DOI: 10.1186/s12935-021-02084-7

Year: 2021

Expression of the NEK family in normal and cancer tissue: an immunohistochemical study

DOI: 10.1186/s12885-019-6408-4

Year: 2020

Body Mass Index and Prognosis of COVID-19 Infection. A Systematic Review

DOI: 10.3389/fendo.2020.00562

Year: 2020

RORγt may Influence the Microenvironment of Thyroid Cancer Predicting Favorable Prognosis

DOI: 10.1038/s41598-020-60280-3

Year: 2020

MON-522 In Silico Analysis of Polymorphism rs2228638 in Neuropillin-1 Demonstrated That This Variant May Hinder EBV Entry into Epithelial Cells

DOI: 10.1210/jendso/bvaa046.1842

Year: 2020

MON-500 Cell Adhesion Molecules mRNA Expression in Thyroid Tumors

DOI: 10.1210/jendso/bvaa046.1755

Year: 2020

A practical contemporary approach to decision-making on subclinical hypothyroidism.

DOI: 10.20945/2359-3997000000317

Year: 2020

What Is the Future of PARP Inhibitors?

What Types of Cancer Are Treated with PARP Inhibitors?

How Do These Mutagens Affect DNA?

Why is Sequencing Important for Studying Genetic Mutations?

What are Immunotherapies?

How Does Hydroxyurea Affect Genetic Mutations?

What is the Delta F508 Mutation?

How Do Genes Work?

Can Neurodevelopmental Disorders Be Prevented?

What Are the Challenges in Phylogenetic Analysis?

Partnered Content Networks

Relevant Topics